Clinical bottom line
Monoclonal antibody (mAb) therapies have transformed allergy management by targeting specific immune pathways, but allergic reactions to these agents remain a clinical challenge. Recent studies highlight improved understanding of the immunopathophysiology of mAb-related hypersensitivity and emerging strategies for diagnosis and management, including dose optimization, desensitization protocols, and personalized risk assessment. While most reactions are mild to moderate, severe anaphylaxis can occur, underscoring the need for vigilance in allergy practice. Advances in clinical trials and real-world data provide guidance on balancing efficacy with safety in mAb use for allergic diseases (Metz et al., 2026; Kind et al., 2026).
What the evidence shows
Metz et al. (2026) conducted a randomized dose-finding study of anti-KIT barzolvolimab in chronic spontaneous urticaria, reporting a favorable safety profile with low incidence of hypersensitivity reactions. This trial exemplifies the importance of dose optimization to minimize allergic adverse events.
Kind et al. (2026) analyzed real-world safety data for lebrikizumab in atopic dermatitis, confirming low rates of infusion-related reactions and hypersensitivity, supporting its tolerability across diverse patient populations.
Schlosser et al. (2025) reviewed long-term outcomes of systemic agents in atopic dermatitis, noting that allergic reactions to mAbs are infrequent but warrant monitoring, particularly during initiation and dose escalation phases.
The 2020 Asian Pacific Journal of Allergy and Immunology review emphasized that allergic reactions to mAbs range from mild infusion reactions to IgE-mediated anaphylaxis, with mechanisms involving immune complex formation and complement activation. It also highlighted the role of premedication and desensitization protocols in managing these reactions.
Danzig et al. (1997) provided foundational evidence that targeting interleukin-5 with mAbs attenuates allergic inflammation, illustrating the therapeutic potential balanced against immunogenicity risks.
Caveats and uncertainty
Data on allergic reactions to newer mAbs remain limited, especially in pediatric and comorbid populations.
Heterogeneity in reporting and classification of hypersensitivity reactions complicates risk stratification.
Mechanistic understanding of non-IgE-mediated reactions is incomplete, limiting predictive biomarker development.
Desensitization protocols require specialized expertise and are not universally available.
Long-term immunogenicity and impact on treatment adherence need further study.
How this may change practice
Clinicians should incorporate vigilant monitoring for allergic reactions during mAb therapy initiation and dose adjustments.
Dose-finding studies and real-world safety data can guide personalized dosing to minimize hypersensitivity risk.
Premedication and desensitization strategies should be considered for patients with prior reactions to maintain therapeutic options.
Enhanced patient education on recognizing and reporting allergic symptoms is critical.
Integration of emerging biomarkers and AI-driven risk prediction may improve individualized management in the future.